Botha P L, Vorster E, Jordaan C
Department of Medical Microbiology, University of the Orange Free State, Bloemfontein, OFS.
S Afr Med J. 1991 Mar 16;79(6):312-3.
In vitro activity of the new bicyclic pyrazolidinone LY 193239 (Eli Lilly) was evaluated against 52 clinical isolates of Haemophilus influenzae (4 were beta-lactamase producers), 32 Enterococcus faecalis, 14 Neisseria gonorrhoeae (1 beta-lactamase-positive) and 19 Neisseria meningitidis. Activity was best against Neisseria spp. and H. influenzae, including penicillinase-producing strains. Results of the time-kill study against a non-enzyme-mediated penicillin resistant strain of N. meningitidis indicate that exposure to an antibacterial concentration four times the minimal inhibitory concentration was bactericidal. E. faecalis was insensitive.
对新型双环吡唑烷酮LY 193239(礼来公司)的体外活性进行了评估,受试菌株包括52株流感嗜血杆菌临床分离株(4株产β-内酰胺酶)、32株粪肠球菌、14株淋病奈瑟菌(1株β-内酰胺酶阳性)和19株脑膜炎奈瑟菌。其活性对奈瑟菌属和流感嗜血杆菌最佳,包括产青霉素酶菌株。针对一株非酶介导的青霉素耐药脑膜炎奈瑟菌的时间-杀菌研究结果表明,暴露于四倍于最低抑菌浓度的抗菌浓度具有杀菌作用。粪肠球菌不敏感。